CEL SCI Corp (CVM) stock
Close on Nov 11, 2026Market cap $23.04MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $23.04M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.10
- Dividend yield
- –
- Free cash flow yield
- -72.70%
Fundamentals
- Net income
- -$22.70M
- EPS, diluted
- -$6.27
- Free cash flow
- -$16.75M
- Book value per share
- $0.90
- Diluted shares
- 12M
Trading
- Previous close
- $1.41
- Open
- $1.41
- Day's range
- $1.28 – $1.43
- Volume
- 87,970
- Average volume (20 days)
- 106,297
- Beta (5 years)
- 1.86
- 52-week range
- $0.89 – $7.80
- RSI (14 days)
- 38.3
- Volatility (1 year)
- 109.1%
- Relative volume
- 0.41×
- WACC
- 14.2%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CVM | S&P 500 | Difference | CVM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.5% | -2.4% | −30.1 pts | ||
| 3 months | -13.8% | -1.2% | −12.7 pts | ||
| Year to date | -75.1% | +12.3% | −87.4 pts | ||
| 1 year | -81.5% | +12.4% | −93.9 pts | ||
| 3 years | -98.1% | +78.8% | −176.9 pts | -73.5% | +21.4% |
| 5 years | -99.6% | +75.2% | −174.8 pts | -67.4% | +11.9% |
| 10 years | -99.4% | +311.1% | −410.5 pts | -40.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cel Sci filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Cel Sci
Biological Products, (No Diagnostic Substances)
CEL-SCI Corporation is a clinical-stage biotechnology company focused on researching and developing immunotherapies to treat cancer and other diseases by activating the body's immune system. Its lead product candidate is Multikine, an investigational leukocyte interleukin injection intended as a first-line neoadjuvant treatment for adult patients with newly diagnosed, resectable locally advanced primary squamous cell carcinoma of the head and neck. Additionally, the company is developing product candidates based on its proprietary Ligand Epitope Antigen Presentation System technology for autoimmune conditions, including rheumatoid arthritis. Because its candidates are investigational and pending regulatory approval, CEL-SCI's customers primarily comprise commercial and distribution partners, clinical trial collaborators, and potential healthcare providers.
Company profile, executives and historyCel Sci stock: common questions
What is Cel Sci's stock price?
CVM closed at $1.31 on Nov 11, 2026, down 7.09% on the day. Over the past 52 weeks it traded between $0.89 and $7.80.
What is Cel Sci's market cap?
Cel Sci was worth $23.04M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CVM's P/E ratio?
Cel Sci lost money over fiscal 2025 (diluted EPS -$6.27), so it has no meaningful P/E ratio.
Does Cel Sci pay a dividend?
No. Cel Sci has not paid a cash dividend over the last twelve months.
How has CVM stock performed over the past year?
Including dividends, CVM returned -81.5% over the past year, against +12.4% for the S&P 500.
How many CVM shares are sold short?
1M shares were sold short at the latest FINRA report, 4.19% of the float, or 6.0 days of average trading volume.
Who are Cel Sci's competitors?
Companies most similar to Cel Sci by business, industry and size include CGEM, TCRX, IBRX, IOVA, CADL.
See a number that looks wrong?